ImmunoGen bags ADC deal with Novartis

Antibody-drug conjugate superstar ImmunoGen ($IMGN) has signed another agreement to lend its targeted drug technology to Novartis ($NVS) for an undisclosed cancer therapy. The latest license is part of a 2010 deal between the two, under which ImmunoGen could reap $200 million plus royalties on any approved drugs. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.